Top

Published in:

01-12-2006

Survival Analysis and Clinicopathological Factors Associated With False-Negative Sentinel Lymph Node Biopsy Findings in Patients with Cutaneous Melanoma

Authors: Zbigniew I. Nowecki, MD, PhD, Piotr Rutkowski, MD, PhD, Anna Nasierowska-Guttmejer, MD, PhD, Wlodzimierz Ruka, MD, PhD

Published in: Annals of Surgical Oncology | Issue 12/2006

Abstract

Background

We analyzed the outcomes and factors associated with false-negative (FN) results of sentinel lymph node (SLN) biopsy findings in patients with cutaneous melanoma. SLN biopsy failure rate was defined as nodal recurrence in the biopsied regional basin without previous local or in-transit recurrence.

Methods

Between April 1997 and December 2004, a total of 1207 patients with cutaneous melanoma with a median Breslow thickness of 2.4 mm underwent SLN biopsy by preoperative and intraoperative lymphoscintigraphy combined with dye injection. In 228 cases, we found positive SLNs; of these, 220 underwent completion lymph node dissection (CLND). Median follow-up was 3 years.

Results

The SLN biopsy failure rate was 5.8% (57 of 979 SLN negative). Median time to occurrence of FN relapse after SLN biopsy was 16 months (range, 3–74 months). The FN SLN biopsy results correlated with primary tumor thickness >4 mm (P = .0012), primary tumor ulceration (P = .0002), primary tumor level of invasion Clark stage IV/V (P = .0005), and nodular melanoma histological type (P = .0375). Five-year overall survival, calculated from the date of primary tumor excision, in the FN group was 53.7%, which was not statistically significantly worse than the CLND group (56.8%; P = .9). The FN group was characterized by a higher ratio of two or more metastatic nodes and extracapsular involvement of lymph nodes after LND compared with the CLND group (P < .0001 and P < .0001, respectively). Additional detailed pathological review of FN SLN revealed metastatic disease in 14 patients, which decreased the SLN biopsy failure rate to 4.4% (43 of 979).

Conclusions

Survival of patients with FN results of SLN biopsy does not differ statistically significantly from that of patients undergoing CLND, although it is slightly lower. The SLN biopsy failure rate is approximately 5.0% in long-term follow-up and is associated mainly with the same factors that indicate a poor prognosis in primary melanoma.

Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127:392–9PubMed

Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17:976–83PubMed

Statius Muller MG, van Leeuwen PA, de Lange-De Klerk ES, et al. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with stage I or II cutaneous melanoma. Cancer 2001; 91:2401–8PubMedCrossRef

Cascinelli N. WHO declares lymphatic mapping to be standard of care for melanoma. Oncology 1999; 13:288

Cascinelli N, Belli F, Santinami M, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol 2000; 7:469–74PubMedCrossRef

Balch Ch M, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635–48

Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma—a multicenter trial. Ann Surg 1999; 4:453–65CrossRef

Morton DL, Thompson JF, Cochran AJ, Essner R, Elashoff R. Interim results of the Multicenter Selective Lymphadenectomy Trial (MSLT-I) in clinical stage I melanoma (abstract 7500). J Clin Oncol 2005; 23(suppl):710s

Nowecki ZI, Rutkowski P, Nasierowska-Guttmejer A, Ruka W. Sentinel lymph node biopsy in clinically N0 melanoma patients—one institution experience. Melanoma Res 2003; 13:35–43PubMedCrossRef

10.

Cook MG, Green Ma, Anderson B, et al. The development of optimal assessment of sentinel lymph nodes for melanoma. J Pathol 2003; 200:314–9PubMedCrossRef

11.

McMasters KM, Reintgen DS, Ross MI, et al. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J Clin Oncol 2001; 19:2851–5PubMed

12.

Morton D, Chan A. Current status of intraoperative lymphatic mapping and sentinel lymphadenectomy for melanoma: is it standard of care? J Am Coll Surg 1999; 189:214–23PubMedCrossRef

13.

Fincher TR, McCarthy TM, Fischer TL, et al. Patterns of recurrence after sentinel lymph node biopsy for cutaneous melanoma. Am J Surg 2003; 186:675–81PubMedCrossRef

14.

Wagner JD, Ranieri J, Evdokimow DZ, et al. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma. Plast Reconstr Surg 2003; 112:486–97PubMedCrossRef

15.

Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998; 16:2253–60PubMed

16.

Clary BM, Mann B, Brady MS, Lewis JL, Coit DG. Early recurrence after lymphatic mapping and sentinel node biopsy with primary extremity melanoma: a comparison with elective lymph node dissection. Ann Surg Oncol 2001; 8:328–37PubMedCrossRef

17.

Jacobs IA, Chevinsky AH, Swayne LC, Magidson JG, Britto EJ, Smith TJ. Gamma probe-directed lymphatic mapping and sentinel lymphadenectomy in primary melanoma: reliability of the procedure and analysis of failures after long-term follow-up. J Surg Oncol 2001; 77:157–64PubMedCrossRef

18.

Statius Muller MG, Borgenstein PJ, Pipjers R, et al. Reliability of the sentinel node procedure in melanoma patients: analysis of failures after long-term follow-up. Ann Surg Oncol 2000; 7:461–8PubMedCrossRef

19.

Vuylsteke RJCLM, van Leeuwen PAM, Statius Muller MG, Gietema HA, Kragt DR, Meijer S. Clinical outcome of stage I/II melanoma patients after selective lymph node dissection: long term follow-up results. J Clin Oncol 2003; 21:1057–65PubMedCrossRef

20.

Gadd MA, Cosimi AB, Yu J, et al. Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch Surg 1999; 134:381–7PubMedCrossRef

21.

Chao C, Wong SL, Ross MI, et al. Patterns of recurrence after sentinel lymph node biopsy for melanoma. Am J Surg 2002; 184:520–5PubMedCrossRef

22.

Statius-Mueller MG, van Leeuwen PA, Van Diest PJ, et al. Pattern and incidence of the first site recurrences following sentinel node procedure in melanoma patients. World J Surg 2002; 26:1405–11CrossRef

23.

Duprat JP, Silva DC, Coimbra FJ, et al. Sentinel lymph node biopsy in cutaneous melanoma: analysis of 240 consecutive cases. Plast Reconstr Surg 2005; 115:1944–51; discussion 1952–3PubMedCrossRef

24.

Jansen L, Nieweg OE, Peterse JL, Hoefnagel CA, Olmos RA, Kroon BB. Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg 2000; 87:484–9PubMedCrossRef

25.

Estourgie SH, Nieweg OE, Valdes Olmos RA, Hoefnagel CA, Kroon BB. Review and evaluation of sentinel node procedures in 250 melanoma patients with median follow-up of 6 years. Ann Surg Oncol 2003; 10:681–8PubMedCrossRef

26.

Yee VS, Thompson JF, McKinnon JG, et al. Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy. Ann Surg Oncol 2005; 12:429–39PubMedCrossRef

27.

Doting MHE, Hoekstra HJ, Plukker JThM, et al. Is sentinel node biopsy beneficial in melanoma patients? A report on 200 patients with cutaneous melanoma. Eur J Surg Oncol 2002; 28:673–678PubMedCrossRef

28.

Scolyer RA, Thompson JF, Li LX, et al. Failure to remove true sentinel nodes can cause failure of the sentinel node biopsy technique: evidence from antimony concentrations in false-negative sentinel nodes from melanoma patients. Ann Surg Oncol 2004; 11(3 suppl):174S–8SPubMed

29.

Stewart LE, Tyler DS, Vollmer RT. The importance of total number of sentinel lymph nodes in patients with stage N0 cutaneous melanoma. Am J Clin Pathol 2005; 124:77–82PubMedCrossRef

30.

Porter G, Ross MI, Berman RS, et al. How many lymph nodes are enough during sentinel lymphadenectomy for primary melanoma? Surgery 2000; 128:306–11PubMedCrossRef

31.

Gershenwald JE, Mansfield PF, Lee JF, Ross MI. Role for lymphatic mapping an sentinel lymph node biopsy in patients with thick (≥4 mm) primary melanoma. Ann Surg Oncol 2000; 7:160–5PubMedCrossRef

32.

Pawlik TM, Ross MI, Thompson JF, Eggermont AMM, Gershenwald JE. The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol 2005; 23:4588–90PubMedCrossRef

33.

Rutkowski P, Nowecki ZI, Zurawski Z, et al. In-transit/local recurrences in melanoma patients after sentinel node biopsy and therapeutic lymph node dissection. Eur J Cancer 2006; 42:159–64PubMedCrossRef

34.

Pawlik TM, Ross MI, Johnson MM, et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol 2005; 12:587–96PubMedCrossRef

35.

Niakosari F, Kahn HJ, Marks A, From L. Detection of lymphatic invasion in primary melanoma with monoclonal antibody D2-40: a selective immunohistochemical marker of lymphatic endothelium. Arch Dermatol 2005; 141:440–4PubMedCrossRef

36.

van Akkooi ACJ, de Wilt JHW, Verhoef C, et al. High positive sentinel node identification rate by EORTC Melanoma Group protocol: prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma. Eur J Cancer 2006; 42:372–80PubMedCrossRef

37.

Li LX, Scolyer RA, Ka VS, et al. Pathologic review of negative sentinel lymph nodes in melanoma patients with regional recurrence: a clinicopathologic study of 1152 patients undergoing sentinel lymph node biopsy. Am J Surg Pathol 2003; 27:1197–202PubMedCrossRef

38.

Starz H. Pathology of the sentinel lymph node in melanoma. Semin Oncol 2004; 31:357–62PubMedCrossRef

39.

Roberts AA, Cochran AJ. Pathologic analysis of sentinel lymph nodes in melanoma patients: current and future trends. J Surg Oncol 2004; 85:152–61PubMedCrossRef

40.

Ruiter DJ, Spatz A, van der Oord JJ, Cook MG. Pathologic staging of melanoma. Semin Oncol 2002; 29:370–81PubMedCrossRef

41.

Cochran AJ, Balda BR, Starz H, et al. The Augsburg Consensus—techniques of lymphatic mapping, sentinel lymphadenectomy and completion lymphadenectomy in cutaneous malignancies. Cancer 2000; 89:236–41PubMedCrossRef

42.

Kuo CT, Hoon DS, Takeuchi H, et al. Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. J Clin Oncol 2003; 21:3566–72PubMedCrossRef

43.

Li W, Stall A, Shivers SC, Lin et al. Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. Ann Surg 2000; 231:795–803

44.

Sung J, Wenbin L, Shivers S, Reintgen D. Molecular analysis in evaluating the sentinel node in malignant melanoma. Ann Surg Oncol 2001; 8(9 suppl):29–30

45.

Cochrane AJ, Wen D-R, Morton DL. Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma: an immunohistochemical study. Am Surg Pathol 1988; 12:612–8CrossRef

46.

Cochran AJ, Huang RR, Guo J, Wen D-R. Current practice and future directions in pathology and laboratory evaluation in the sentinel node. Ann Surg Oncol 2001; 8(suppl):13–7

47.

McMasters KM, Noyes RD, Reintgen DS, et al. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol 2004; 86:212–23PubMedCrossRef

48.

Shen J, Wallace AM, Bouvet M. The role of sentinel lymph node biopsy for melanoma. Semin Oncol 2002; 29:341–52PubMedCrossRef

Title: Survival Analysis and Clinicopathological Factors Associated With False-Negative Sentinel Lymph Node Biopsy Findings in Patients with Cutaneous Melanoma
Authors: Zbigniew I. Nowecki, MD, PhD
Piotr Rutkowski, MD, PhD
Anna Nasierowska-Guttmejer, MD, PhD
Wlodzimierz Ruka, MD, PhD
Publication date: 01-12-2006
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 12/2006
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-006-9066-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Survival Analysis and Clinicopathological Factors Associated With False-Negative Sentinel Lymph Node Biopsy Findings in Patients with Cutaneous Melanoma

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2006

Nuclear Translocation of β-Catenin Protein but Absence of β-Catenin and APC Mutation in Gastrointestinal Carcinoid Tumor

Clinical Implications of Combined Portal Vein Resection as a Palliative Procedure in Patients Undergoing Pancreaticoduodenectomy for Pancreatic Head Carcinoma

Sonographically Guided Fine Needle Aspiration with Rapid Parathyroid Hormone Assay

A Dangerous Liaison—Pheochromocytoma in Patients with Malignant Disease

Immunohistochemical Expression of p16INK4A, Ki-67, and Mcm2 Proteins in Gastrointestinal Stromal Tumors: Prognostic Implications and Correlations with Risk Stratification of NIH Consensus Criteria

REG I Expression Predicts Long-term Survival among Locally Advanced Thoracic Squamous Cell Esophageal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy Followed by Esophagectomy